EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 159 filers reported holding EXELIXIS INC in Q1 2014. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $62,673,459 | -14.7% | 2,789,206 | -8.9% | 0.01% | -30.8% |
Q4 2023 | $73,448,912 | +35.3% | 3,061,647 | +7.7% | 0.01% | +18.2% |
Q2 2023 | $54,304,486 | +0.8% | 2,841,679 | +2.4% | 0.01% | -8.3% |
Q1 2023 | $53,861,547 | +5.7% | 2,774,938 | -12.6% | 0.01% | 0.0% |
Q4 2022 | $50,953,257 | +11.2% | 3,176,637 | +8.7% | 0.01% | 0.0% |
Q3 2022 | $45,833,879 | -21.8% | 2,923,079 | +3.8% | 0.01% | -20.0% |
Q2 2022 | $58,611,069 | -9.2% | 2,815,133 | -1.1% | 0.02% | +7.1% |
Q1 2022 | $64,516,122 | +16.4% | 2,845,881 | -6.2% | 0.01% | +27.3% |
Q4 2021 | $55,443,000 | -8.1% | 3,032,964 | +6.3% | 0.01% | -15.4% |
Q3 2021 | $60,339,000 | +16.0% | 2,854,257 | 0.0% | 0.01% | +18.2% |
Q2 2021 | $52,005,000 | -20.3% | 2,854,257 | -1.1% | 0.01% | -26.7% |
Q1 2021 | $65,211,000 | +7.1% | 2,886,714 | -4.9% | 0.02% | +7.1% |
Q4 2020 | $60,911,000 | -19.9% | 3,034,931 | -2.4% | 0.01% | -30.0% |
Q3 2020 | $76,015,000 | +6.4% | 3,108,980 | +3.3% | 0.02% | -4.8% |
Q2 2020 | $71,468,000 | +40.4% | 3,010,435 | +1.9% | 0.02% | +16.7% |
Q1 2020 | $50,892,000 | -2.3% | 2,955,427 | 0.0% | 0.02% | +20.0% |
Q4 2019 | $52,075,000 | -2.7% | 2,955,427 | -2.3% | 0.02% | -6.2% |
Q3 2019 | $53,516,000 | -13.3% | 3,026,054 | +4.7% | 0.02% | -15.8% |
Q2 2019 | $61,741,000 | -8.3% | 2,889,131 | +2.1% | 0.02% | -13.6% |
Q1 2019 | $67,327,000 | +23.2% | 2,828,860 | +1.8% | 0.02% | +10.0% |
Q4 2018 | $54,640,000 | +21.6% | 2,777,840 | +9.5% | 0.02% | +33.3% |
Q3 2018 | $44,946,000 | -17.7% | 2,536,452 | 0.0% | 0.02% | -21.1% |
Q2 2018 | $54,584,000 | +0.9% | 2,536,452 | +3.8% | 0.02% | -5.0% |
Q1 2018 | $54,104,000 | -23.5% | 2,442,655 | +5.0% | 0.02% | -20.0% |
Q4 2017 | $70,725,000 | +25.5% | 2,326,500 | 0.0% | 0.02% | +19.0% |
Q3 2017 | $56,371,000 | -1.6% | 2,326,500 | 0.0% | 0.02% | -8.7% |
Q2 2017 | $57,302,000 | +20.4% | 2,326,500 | +5.9% | 0.02% | +15.0% |
Q1 2017 | $47,594,000 | +29.0% | 2,196,301 | -11.2% | 0.02% | +25.0% |
Q4 2016 | $36,882,000 | +57.2% | 2,473,654 | +28.8% | 0.02% | +45.5% |
Q3 2016 | $23,460,000 | +134.9% | 1,920,464 | +50.2% | 0.01% | +120.0% |
Q2 2016 | $9,987,000 | +373.1% | 1,278,794 | +55.7% | 0.01% | +400.0% |
Q1 2015 | $2,111,000 | +55.8% | 821,439 | -12.7% | 0.00% | 0.0% |
Q4 2014 | $1,355,000 | -35.7% | 941,110 | -31.7% | 0.00% | 0.0% |
Q3 2014 | $2,108,000 | -77.4% | 1,378,002 | -50.0% | 0.00% | -66.7% |
Q2 2014 | $9,344,000 | +91.6% | 2,756,004 | +100.0% | 0.00% | 0.0% |
Q1 2014 | $4,878,000 | -42.3% | 1,378,002 | 0.0% | 0.00% | -40.0% |
Q4 2013 | $8,447,000 | +1.6% | 1,378,002 | -3.5% | 0.01% | 0.0% |
Q3 2013 | $8,311,000 | +79.1% | 1,428,054 | +39.7% | 0.01% | +66.7% |
Q2 2013 | $4,641,000 | +68.3% | 1,022,333 | +71.2% | 0.00% | +50.0% |
Q1 2013 | $2,758,000 | -4.2% | 597,115 | 0.0% | 0.00% | 0.0% |
Q3 2012 | $2,878,000 | -28.6% | 597,115 | -7.4% | 0.00% | -33.3% |
Q2 2012 | $4,031,000 | – | 644,971 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
Signition LP | 84,120 | $1,798,000,000 | 1.18% |
Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |